Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. - Wikidata - wikimedia - TriplyDB

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.

http://www.wikidata.org/entity/Q34227891

about

Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies Efficacy and safety of canagliflozin among patients with type 2 diabetes mellitus: A systematic review and meta-analysis Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus Cardiovascular Risk in Diabetes Mellitus: Complication of the Disease or of Antihyperglycemic Medications Treating the elderly diabetic patient: special considerations The Diabetes Intention, Attitude, and Behavior Questionnaire: evaluation of a brief questionnaire to measure physical activity, dietary control, maintenance of a healthy weight, and psychological antecedents Canagliflozin: Efficacy and Safety in Combination with Metformin Alone or with Other Antihyperglycemic Agents in Type 2 Diabetes Sodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effects Comparative effectiveness of sodium-glucose co-transporter 2 inhibitors for controlling hyperglycaemia in patients with type 2 diabetes: protocol for a systematic review and network meta-analysis Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors from Natural Products: Discovery of Next-Generation Antihyperglycemic Agents Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials Risk of diarrhea in patients with type 2 diabetes mellitus treated with sitagliptin: a meta-analysis of 30 randomized clinical trials Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysis Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials.The role of kidney in glucose homeostasis--SGLT2 inhibitors, a new approach in diabetes treatment.Sodium-Glucose linked transporter 2 (SGLT2) inhibitors--fighting diabetes from a new perspective.Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data.Adverse drug events observed in patients with type 2 diabetes mellitus treated with 100 mg versus 300 mg canagliflozin: a systematic review and meta-analysis of published randomized controlled trials Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies The Relationship between Increases in Morning Spot Urinary Glucose Excretion and Decreases in HbA1C in Patients with Type 2 Diabetes After Taking an SGLT2 Inhibitor: A Retrospective, Longitudinal Study.Canagliflozin-current status in the treatment of type 2 diabetes mellitus with focus on clinical trial data.Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial.Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes.Emerging treatments in type 2 diabetes: focus on canagliflozin.A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor.A Review on the Relationship between SGLT2 Inhibitors and Cancer.Update on developments with SGLT2 inhibitors in the management of type 2 diabetes Pharmacokinetic and pharmacodynamic profiles of canagliflozin in Japanese patients with type 2 diabetes mellitus and moderate renal impairment.A clinical perspective of canagliflozin in the management of type 2 diabetes mellitus.Canagliflozin: a novel treatment option for type 2 diabetes.Randomized trial showing efficacy and safety of twice-daily remogliflozin etabonate for the treatment of type 2 diabetes.Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes.Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial Canagliflozin: effects in overweight and obese subjects without diabetes mellitus.Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan.Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trials

P2860

Q26765047-A64646F2-DFE3-4E4B-9E09-4274D675D074 Q26773558-9CA7095F-146C-416B-A6BF-97FBE6898B9A Q26777529-67A9041B-84E1-41CC-8471-B4F091F8AC44 Q26824616-A85A603D-7638-4095-ACAE-456B3E6DC267 Q26995176-519FCBB0-FD6B-4272-94E9-FAC8CA5C5490 Q27336003-A376E754-8BE4-4B52-A958-36806E32EB08 Q28072339-B664117C-7DBC-4BCB-A590-11EA8EBF4A5F Q28072765-0BE23145-16C8-49DB-83F5-96EF8DD590B9 Q28074573-5C29B8A2-87C6-4685-A57D-0D9511F8C409 Q28074843-3CE71F5A-1F21-410D-A8F7-2641E903853A Q28294225-0FCC5A2A-6E5A-4CA4-9F7E-0CE53C60307C Q28544980-FDF567F2-BB18-4408-B215-5224CF04F939 Q28546797-97460D14-FD89-4A81-B3EC-F661D29887D9 Q28553482-29DB7211-8800-47DE-A359-EEF30D712B81 Q30248634-6275AFB3-899F-4D65-88FF-6DAE3BC3FFFB Q30663494-71887CB8-C9A0-4D85-B8A6-B809917EEFFE Q30833760-B9745087-F45A-4EA8-ACEE-6B41BBA6557B Q30903369-D2660A9A-D147-4B74-9785-DEBEC2E503F0 Q33567077-D560D539-557A-4603-9A4E-A622A5F93A26 Q33613143-7865E534-63CD-4066-9B47-5E46F7010147 Q33732583-6DE4F07D-7134-4AFB-B37F-306E4D9EBF34 Q33759610-65040735-0A76-4F22-BBBA-F08BB80CE607 Q33785136-5753FB46-CBE0-4A07-A60A-27490405A96A Q34105064-093F1013-7676-4EED-B0E8-C5ED697C6A9F Q34109789-46487557-1D70-4DD0-912A-161C9D57DE0F Q34161881-7D3A7733-02C8-4106-A02A-027BC627FBC2 Q34181385-10E2FF89-9F08-4614-9CA5-B92E7253B905 Q34198692-4AF59E98-E31C-4770-AA5D-13C567E02690 Q34208581-FA632A88-A616-42FB-B54E-5ECCC1F34561 Q34264365-98E58CEC-AE34-4E80-853B-8C3FB1FF860E Q34388544-DFD304DD-D5D3-4792-BD69-8CE1C09892D4 Q34438769-21DB57B4-E16B-4FC5-95A7-859549729975 Q34453811-34020B0F-1A08-4F10-A894-85C851083E42 Q34543009-D900AEC3-BA3F-47F6-9B58-70CD075BD3F9 Q34646948-C7BAB7B9-D270-4A9A-8663-1351FB2C101D Q34699217-7A72DDA4-AB00-46D7-9D65-7987CFD12379 Q34804900-4B1B8179-BCB2-4866-9B5D-5EFA4210E7DD Q34851219-80FDB2BF-3790-42C7-B004-113009C436FF Q35049845-4D56E0CA-9412-4F8B-80B7-9E5C62279067 Q35068181-FD1F4124-0223-4CF0-A706-A741AB54A48C

P2860

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.

http://www.wikidata.org/entity/Q34227891

description

2012 nî lūn-bûn

@nan

2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Dose-ranging effects of canagl ...... subjects with type 2 diabetes.

@ast

Dose-ranging effects of canagl ...... subjects with type 2 diabetes.

@en

Dose-ranging effects of canagl ...... subjects with type 2 diabetes.

@nl

type

label

Dose-ranging effects of canagl ...... subjects with type 2 diabetes.

@ast

Dose-ranging effects of canagl ...... subjects with type 2 diabetes.

@en

Dose-ranging effects of canagl ...... subjects with type 2 diabetes.

@nl

prefLabel

Dose-ranging effects of canagl ...... subjects with type 2 diabetes.

@ast

Dose-ranging effects of canagl ...... subjects with type 2 diabetes.

@en

Dose-ranging effects of canagl ...... subjects with type 2 diabetes.

@nl

P1433

Q34227891-622A32DB-4F61-4296-923D-9EF2EEC1A6ED

P1476

Q34227891-EC875122-8C9C-4307-98D2-EC956F94FF70

P2093

Q34227891-355CBEE5-6F1C-4EDA-9F0B-398165A582FE

Q34227891-547AF401-6D80-44AC-845E-1983632E1464

Q34227891-5687B6EC-46B3-43EA-9414-9FE628F950A8

Q34227891-56CB900F-8E53-4C78-B6B4-42A637DD4FBB

Q34227891-77506DEC-1D6D-4294-8AAB-E6A3D16B861E

Q34227891-9CA06E43-5DF1-4B29-BDBC-ADD979CD46EE

Q34227891-EA81CDDA-7FD5-4FD5-B7EF-623EBAF8342C

Q34227891-F96B820B-863E-466D-9D13-216E89037ED7

P2860

Q34227891-2189D434-DF23-4D8E-B1BC-F8EDE1DA911D

Q34227891-21D8BA55-9538-4909-A455-3B48FC166B00

Q34227891-3112143D-23CC-4696-8F09-D8D5688C4B22

Q34227891-438D22B7-866E-4EBC-B542-C388C7F8474D

Q34227891-45E1ED25-E6E0-40B0-A134-F096C32EACAC

Q34227891-4AD25AAD-43A7-4064-9BD0-054B13C65AAF

Q34227891-4F2A5990-13D7-434E-8171-92A04BFECE0F

Q34227891-67F8E357-3A86-444E-BF13-90FDEFBA4595

Q34227891-AA5831DE-2149-4A96-841A-C9B8F458D605

Q34227891-DDECE08E-64D0-4EC2-94FC-E17B38D77CDC

P304

Q34227891-A28C7BFE-CE16-43D4-8CCB-87FAFBF8E432

P31

Q34227891-162FEE0A-1195-45A7-9C2B-ABE3B524D815

P356

Q34227891-E6BB0D62-E027-4B17-8A71-E6892CB9E1A6

P407

Q34227891-DF274284-A430-4481-917B-A0972BB787C3

P433

Q34227891-EF953A77-EE8C-4D23-991E-F66A976A05EC

P478

Q34227891-D1A8B651-C8B4-4EDB-B3E3-C20E84679A0C

P50

Q34227891-F130F928-2CB5-4E04-B6D4-9022955B1817

P577

Q34227891-4B5F0303-1042-4D86-8C66-708119947E4A

P5875

Q34227891-22E195B6-A985-4626-B3C3-A04277E9C889

P698

Q34227891-E3DD8893-352B-4D82-B4B4-EDD6C4168F3B

P921

Q34227891-005EC682-94FE-4AFF-ACE2-7AFCD803FEA2

Q34227891-38E922CD-77B9-4C8D-AFE8-D245A0430080

Q34227891-3E0B2D26-92BE-4BC5-9411-E73A9560AD38

Q34227891-91b1f528-524d-4cf3-bf25-50cbd270ad02

Q34227891-C6F5FB01-D5FA-4793-B487-61DA48C73F1F

P932

Q34227891-52A9BBC1-9DD7-49F4-B10B-96574D43BB3A

P356

P1433

P1476

Dose-ranging effects of canagl ...... subjects with type 2 diabetes.

@en

P2093

Canagliflozin DIA 2001 Study Group

http://www.w3.org/2001/XMLSchema#string

David Polidori

http://www.w3.org/2001/XMLSchema#string

Deborah Arbit

http://www.w3.org/2001/XMLSchema#string

George Capuano

http://www.w3.org/2001/XMLSchema#string

Keith Usiskin

http://www.w3.org/2001/XMLSchema#string

Naresh Aggarwal

http://www.w3.org/2001/XMLSchema#string

William Canovatchel

http://www.w3.org/2001/XMLSchema#string

Yue Zhao

http://www.w3.org/2001/XMLSchema#string

P2860

Active sugar transport in health and disease

SLC2A9 is a high-capacity urate transporter in humans

A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials.

Approach to renal tubular disorders.

Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications.

Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats.

Effects of weight loss and reduced hyperglycemia on the kinetics of insulin secretion in obese non-insulin dependent diabetes mellitus.

Sodium-glucose transporter-2 inhibition as an antidiabetic therapy.

Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006.

Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects.

P304

1232-1238

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DC11-1926

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

35

http://www.w3.org/2001/XMLSchema#string

P50

Julio Rosenstock

P577

2012-04-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

223973999

http://www.w3.org/2001/XMLSchema#string

P698

22492586

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

canagliflozin hemihydrate

P932

3357223

http://www.w3.org/2001/XMLSchema#string